| Title: |
Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer. |
| Authors: |
Narusawa, Eriko, Kurozumi, Sasagu, Katayama, Ayaka, Koibuchi, Yukio, Ogawa, Akira, Takata, Daisuke, Tokuda, Shoko, Obayashi, Sayaka, Oyama, Tetsunari, Horiguchi, Jun, Shirabe, Ken, Fujii, Takaaki |
| Source: |
Medical Molecular Morphology; Sep2024, Vol. 57 Issue 3, p177-184, 8p |
| Subject Terms: |
TRIPLE-negative breast cancer, PATHOLOGIC complete response, EPIDERMAL growth factor, NEOADJUVANT chemotherapy, BREAST cancer prognosis |
| Abstract: |
In some cases of human epidermal growth factor 2 (HER2)-negative breast cancer, including triple-negative breast cancer, HER2 expression is sporadically and strongly upregulated, a condition known as HER2 heterogeneity. We investigated the clinicopathological features of patients with HER2 heterogeneity in triple-negative breast cancers treated with neoadjuvant chemotherapy. Thirty-nine patients with triple-negative breast cancer who had undergone preoperative chemotherapy participated in this study. To assess for HER2 heterogeneity, we used dual in situ hybridization slides. We evaluated the association between HER2 heterogeneity and clinicopathological factors such as rates of pathologic complete response (pCR) and of recurrence-free survival. Of the 39 patients, 15 (38.5%) had cancers with HER2 heterogeneity. The pCR rates were 13.3% among patients with HER2 heterogeneity and 20.8% among those with HER2 nonheterogeneity, but the difference was not significant. The recurrence-free survival rate was significantly lower in patients with HER2 heterogeneity than in those without (P = 0.025). HER2 heterogeneity is a significant predictor of poor prognosis in patients with triple-negative breast cancer treated with neoadjuvant chemotherapy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Medical Molecular Morphology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
